Infections, Meningococcal
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Infections, Meningococcal trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Infections, Meningococcal trials you may qualify forBacterial meningitis is a major cause of morbidity and mortality in childhood. Antibiotic treatment recommendations are based on epidemiological and susceptibil…
Sexual differences are a well-established source of biological variation in immune system functioning, with men often displaying lower adaptive immune responses…
This clinical trial is conducted in two parts. Part One employs a randomized, partially blinded, dose-escalation, partially active-controlled design. Part Two u…
Assessment of immunogenicity, reactogenicity and safety of GNG-DE in comparison with the reference drug
Primary Objective: To assess maternal, obstetrical, pregnancy, and neonatal and infant outcomes among women vaccinated with MenQuadfi® during pregnancy or in t…
Phase 2/3 study to evaluate immunogenicity and safety in healthy adult participants following a single dose administration of Meningococcal (groups A, C, W-135,…
The bacterium (germ) Neisseria meningitidis causes meningitis and blood poisoning. N meningitidis is classified into different serogroups (types), based on its…
This is a Phase 3, modified double-blind, randomized, parallel-group, active-controlled, multicenter study with 2 arms and 4 groups to evaluate the immunogenici…